Skip to main content

Search

Reset all filters
315 Result(s)
Sort by

Health Canada approves OFEV® (nintedanib), the first and only therapy in Canada to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated ILD

Health Canada approves OFEV® (nintedanib), the first and only therapy in Canada to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated ILD

Health Canada approves OFEV® (nintedanib), the first and only therapy in Canada to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated ILD
Rewards and recognition

Rewards and recognition

There are achievements and occasions that demand recognition. We go out of way to give employees tangible rewards and more for business milestones.